The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...

The studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...

The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

Bengaluru: The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal infection for use in people aged 10 through 25 years, the company ...

Amin Barakat, MD, FAAP, details meningococcal disease vaccines and highlights the recently FDA-approved MenABCWY vaccine from GSK. Invasive meningococcal disease (IMD) is a life-threatening infection ...

The US Food and Drug Administration (FDA) has approved GSK's pentavalent meningococcal vaccine, Penmenvy, for children and young adults aged 10 to 25 years. This new vaccine provides protection ...